Cgmp Pharma 'N' Plans Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 15 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 3.94 M
About Cgmp Pharma 'N' Plans
Cgmp Pharma 'N' Plans Private Limited (CPNPPL) is a Private Limited Indian Non-Government Company incorporated in India on 06 July 2009 and has a history of 15 years and seven months. Its registered office is in Delhi, India.
The Corporate was formerly known as Cgmp Pharmaplan Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹3.94 M.
Ravi Saxena and Neeti Bhardwaj serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74900DL2009PTC191902
-
Company No.
191902
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 Jul 2009
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Cgmp Pharma 'N' Plans?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neeti Bhardwaj
|
Director | 09-Dec-2010 | Current |
|
Ravi Saxena
|
Director | 06-Jul-2009 | Current |
Financial Performance of Cgmp Pharma 'N' Plans.
Cgmp Pharma 'N' Plans Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cgmp Pharma 'N' Plans?
Unlock access to Cgmp Pharma 'N' Plans's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Revacure Lifesciences LlpRavi Saxena and Neeti Bhardwaj are mutual person
Charges (Loans)
₹3.94 M
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.39 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 03 Mar 2023 | Hdfc Bank Limited | ₹3.94 M | Open |
How Many Employees Work at Cgmp Pharma 'N' Plans?
Cgmp Pharma 'N' Plans has a workforce of 9 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cgmp Pharma 'N' Plans, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cgmp Pharma 'N' Plans's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
